Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...

Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, will step down, the agency confirmed ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...

City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...

A Dutch biotech cre­at­ing nasal sprays to pro­tect against the flu and coro­n­avirus has raised an ad­di­tion­al $70 ...

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...